Engineered polypeptides and uses thereof

Abstract

Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

What is claimed is: 
     
         1 . A polypeptide comprising the CH2 and CH3 domains of an Fc region, wherein the CH2 and CH3 domains of the Fc region comprises mutations from any of (i)-(vi):
 (i) T256D, Q311V, and A378V;   (ii) H285N, T307Q, and N315D;   (iii) H285D, T307Q, and A378V;   (iv) T307Q, Q311V, and A378V;   (v) T256D, N286D, T307R, Q311V, and A378V; or   (vi) T256D, H285D, T307R, Q311V, and A378V.   
     
     
         2 . The polypeptide of  claim 1 , which is an isolated polypeptide or a synthetic polypeptide. 
     
     
         3 . The polypeptide of  claim 1 , wherein the CH2 and CH3 domains of the Fc region comprises the mutations T256D, Q311V, and A378V. 
     
     
         4 . The polypeptide of  claim 1 , wherein the CH2 and CH3 domains of the Fc region comprises the mutations H285N, T307Q, and N315D. 
     
     
         5 . The polypeptide of  claim 1 , wherein the CH2 and CH3 domains of the Fc region comprises the mutations H285D, T307Q, and A378V. 
     
     
         6 . The polypeptide of  claim 1 , wherein the CH2 and CH3 domains of the Fc region comprises the mutations T307Q, Q311V, and A378V. 
     
     
         7 . The polypeptide of  claim 1 , wherein the CH2 and CH3 domains of the Fc region comprises the mutations T256D, N286D, T307R, Q311V, and A378V. 
     
     
         8 . The polypeptide of  claim 1 , wherein the CH2 and CH3 domains of the Fc region comprises the mutations T256D, H285D, T307R, Q311V, and A378V. 
     
     
         9 . The polypeptide of  claim 1 , which further comprises a hinge region between the CH2 and CH3 domains of the Fc region. 
     
     
         10 . The polypeptide of  claim 1 , which is an antibody molecule. 
     
     
         11 . The polypeptide of  claim 10 , wherein the antibody molecule is a chimeric antibody molecule or a murine antibody molecule. 
     
     
         12 . The polypeptide of  claim 10 , wherein the antibody molecule is a human antibody molecule or a humanized antibody molecule. 
     
     
         13 . The polypeptide of  claim 1 , which further comprises a heavy chain immunoglobulin variable region, a light chain immunoglobulin variable region, or both. 
     
     
         14 . The polypeptide of  claim 1 , which is an immunoglobulin chain or a fragment thereof. 
     
     
         15 . The polypeptide of  claim 1 , which is a fusion protein. 
     
     
         16 . A composition comprising the polypeptide of  claim 1 . 
     
     
         17 . The composition of  claim 16 , further comprising a pharmaceutically acceptable carrier. 
     
     
         18 . A nucleic acid molecule encoding the polypeptide of  claim 1 . 
     
     
         19 . A vector comprising the nucleic acid molecule of  claim 18 . 
     
     
         20 . A cell comprising the nucleic acid molecule of  claim 18 . 
     
     
         21 . A kit comprising the polypeptide of  claim 1  and instructions to use of the polypeptide. 
     
     
         22 . A container comprising the polypeptide of  claim 1 . 
     
     
         23 . A method of producing a polypeptide, the method comprising culturing the cell of  claim 20  under conditions that allow production of an antibody molecule, thereby producing the polypeptide. 
     
     
         24 . The method of  claim 23 , further comprising isolating or purifying the polypeptide. 
     
     
         25 . A method of treating a disorder, the method comprising administering to a subject in need thereof an effective amount of the polypeptide of  claim 1 , thereby treating the disorder. 
     
     
         26 . A method of detecting a molecule, the method comprising contacting a cell or a sample from a subject with the polypeptide of  claim 1 , thereby detecting the molecule.